Morten Olsen1, Ester Garne2, Claus Sværke1, Lars Søndergaard3, Henrik Nissen4, Henrik Ø Andersen5, Vibeke E Hjortdal6, Søren P Johnsen1, Jørgen Videbæk1. 1. 1 Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark. 2. 2 Department of Paediatrics, Hospital Lillebaelt, Kolding, Denmark. 3. 3 Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Heart Centre, Copenhagen, Denmark. 4. 4 Department of Cardiology, Odense University Hospital, Odense, Denmark. 5. 5 Department of Cardiothoracic Surgery, Rigshospitalet - Copenhagen University Hospital, Heart Centre, Copenhagen, Denmark. 6. 6 Department of Cardiothoracic Surgery, Aarhus University Hospital, Skejby, Aarhus, Denmark.
Abstract
OBJECTIVE: We aimed to assess cancer risk in congenital heart defect patients, with and without Down's syndrome, compared with the general population. METHODS: We identified all patients born and diagnosed with congenital heart defects from 1977 to 2008 using the Danish National Registry of Patients, covering all Danish hospitals. We compared cancer incidence in the congenital heart defect cohort with that expected in the general population (∼5.5 million) using the Danish Cancer Registry, and computed age- and gender-standardised incidence ratios. RESULTS: We identified 15,905 congenital heart defect patients, contributing a total of 151,172 person-years at risk; the maximum length of follow-up was 31 years (median 8 years). In all, 53 patients were diagnosed with cancer, including 30 female and 23 male patients (standardised incidence ratio = 1.63; 95% confidence interval: 1.22-2.13). Risks were increased for leukaemia, brain tumours, and basal cell carcinoma. After excluding 801 patients with Down's syndrome, the standardised incidence ratio was 1.19 (95% confidence interval: 0.84-1.64). In the subgroup of 5660 non-Down's syndrome patients undergoing cardiac surgery or catheter-based interventions, the standardised incidence ratio was 1.45 (95% confidence interval: 0.86-2.29). CONCLUSION: The overall risk of cancer among congenital heart defect patients without Down's syndrome was not statistically significantly elevated. Cancer risk in the congenital heart defect cohort as a whole, including patients with Down's syndrome, was increased compared with the general population, although the absolute risk was low. Studies with longer follow-up and more information on radiation doses are needed to further examine a potential cancer risk associated with diagnostic radiation exposure.
OBJECTIVE: We aimed to assess cancer risk in congenital heart defectpatients, with and without Down's syndrome, compared with the general population. METHODS: We identified all patients born and diagnosed with congenital heart defects from 1977 to 2008 using the Danish National Registry of Patients, covering all Danish hospitals. We compared cancer incidence in the congenital heart defect cohort with that expected in the general population (∼5.5 million) using the Danish Cancer Registry, and computed age- and gender-standardised incidence ratios. RESULTS: We identified 15,905 congenital heart defectpatients, contributing a total of 151,172 person-years at risk; the maximum length of follow-up was 31 years (median 8 years). In all, 53 patients were diagnosed with cancer, including 30 female and 23 male patients (standardised incidence ratio = 1.63; 95% confidence interval: 1.22-2.13). Risks were increased for leukaemia, brain tumours, and basal cell carcinoma. After excluding 801 patients with Down's syndrome, the standardised incidence ratio was 1.19 (95% confidence interval: 0.84-1.64). In the subgroup of 5660 non-Down's syndrome patients undergoing cardiac surgery or catheter-based interventions, the standardised incidence ratio was 1.45 (95% confidence interval: 0.86-2.29). CONCLUSION: The overall risk of cancer among congenital heart defectpatients without Down's syndrome was not statistically significantly elevated. Cancer risk in the congenital heart defect cohort as a whole, including patients with Down's syndrome, was increased compared with the general population, although the absolute risk was low. Studies with longer follow-up and more information on radiation doses are needed to further examine a potential cancer risk associated with diagnostic radiation exposure.
Authors: Nicolas L Madsen; Bradley S Marino; Jessica G Woo; Reimar W Thomsen; Jørgen Videbœk; Henning Bœkgaard Laursen; Morten Olsen Journal: J Am Heart Assoc Date: 2016-07-08 Impact factor: 5.501
Authors: Anne Marie Kirkegaard; Maria Breckling; Dorte Guldbrand Nielsen; Janne S Tolstrup; Søren Paaske Johnsen; Annette Kjær Ersbøll; Stine Kloster Journal: BMC Pregnancy Childbirth Date: 2021-12-07 Impact factor: 3.007